Drug intelligence / Profile preview

getagozumab

Development stage: Unknown
Lead developer: Gmax Biopharm
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Getagozumab (GMA301) is a humanized IgG4 monoclonal antibody that selectively targets the endothelin receptor A (ETA), a G protein-coupled receptor central to the pathogenesis of pulmonary arterial hypertension (PAH). Developed by Gmax Biopharm, it is designed to antagonize the effects of endothelin-1, thereby reducing pulmonary arterial pressure and inhibiting vascular remodeling. Getagozumab has received Orphan Drug Designation from the US FDA and has been evaluated in Phase 1 clinical trials for safety, tolerability, and pharmacokinetics.

Targets

EDNRA (Endothelin receptor type A)

Beyond the preview

Go deeper on getagozumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on getagozumab.

Explore the full profile